Andrew W. Pawluczkowycz

Binding of Submaximal C1q Promotes Complement-Dependent Cytotoxicity (CDC) of B Cells Opsonized with Anti-CD20 mAbs Ofatumumab (OFA) or Rituximab (RTX): Considerably Higher Levels of CDC Are Induced by OFA than by RTX

Andrew W. Pawluczkowycz, Frank J. Beurskens, Paul V. Beum et al. · The Journal of Immunology · 2009 · 254 citations · Full text

Clinical Immunology, Cdc Are Induced, Immunology +18

Thrice-Weekly Low-Dose Rituximab Decreases CD20 Loss via Shaving and Promotes Enhanced Targeting in Chronic Lymphocytic Leukemia

Michael E. Williams, John Densmore, Andrew W. Pawluczkowycz et al. · The Journal of Immunology · 2006 · 148 citations · Full text

Chronic Lymphocytic Leukemia, Immunology, Immunotherapy +17

Complement Activation on B Lymphocytes Opsonized with Rituximab or Ofatumumab Produces Substantial Changes in Membrane Structure Preceding Cell Lysis

Paul V. Beum, Margaret A. Lindorfer, Frank J. Beurskens et al. · The Journal of Immunology · 2008 · 124 citations · Full text

Binding of Rituximab, Trastuzumab, Cetuximab, or mAb T101 to Cancer Cells Promotes Trogocytosis Mediated by THP-1 Cells and Monocytes

Paul V. Beum, David A. Mack, Andrew W. Pawluczkowycz et al. · The Journal of Immunology · 2008 · 90 citations · Full text

Hematin Promotes Complement Alternative Pathway-Mediated Deposition of C3 Activation Fragments on Human Erythrocytes: Potential Implications for the Pathogenesis of Anemia in Malaria

Andrew W. Pawluczkowycz, Margaret A. Lindorfer, John Waitumbi et al. · The Journal of Immunology · 2007 · 86 citations · Full text